Page last updated: 2024-08-25

atovaquone and ER-Negative PR-Negative HER2-Negative Breast Cancer

atovaquone has been researched along with ER-Negative PR-Negative HER2-Negative Breast Cancer in 1 studies

Research

Studies (1)

Timeframe	Studies, this research(%)	All Research%
pre-1990	0 (0.00)	18.7374
1990's	0 (0.00)	18.2507
2000's	0 (0.00)	29.6817
2010's	0 (0.00)	24.3611
2020's	1 (100.00)	2.80

Authors

Authors	Studies
Gaikwad, S; Gupta, N; Kaushik, I; Markiewski, MM; Srivastava, SK; Wright, SE	1

Other Studies

1 other study(ies) available for atovaquone and ER-Negative PR-Negative HER2-Negative Breast Cancer

Article	Year
Atovaquone Suppresses Triple-Negative Breast Tumor Growth by Reducing Immune-Suppressive Cells. International journal of molecular sciences, 2021, May-13, Volume: 22, Issue:10 Topics: Animals; Anti-Infective Agents; Antigen Presentation; Apoptosis; Atovaquone; Cell Proliferation; Cytokines; Female; Humans; Immunosuppression Therapy; Mice; Mice, Inbred BALB C; Mice, Inbred NOD; Mice, SCID; Myeloid-Derived Suppressor Cells; T-Lymphocytes, Regulatory; Triple Negative Breast Neoplasms; Tumor Cells, Cultured; Xenograft Model Antitumor Assays	2021

Article

Year

Atovaquone Suppresses Triple-Negative Breast Tumor Growth by Reducing Immune-Suppressive Cells.

International journal of molecular sciences, 2021, May-13, Volume: 22, Issue:10

Topics: Animals; Anti-Infective Agents; Antigen Presentation; Apoptosis; Atovaquone; Cell Proliferation; Cytokines; Female; Humans; Immunosuppression Therapy; Mice; Mice, Inbred BALB C; Mice, Inbred NOD; Mice, SCID; Myeloid-Derived Suppressor Cells; T-Lymphocytes, Regulatory; Triple Negative Breast Neoplasms; Tumor Cells, Cultured; Xenograft Model Antitumor Assays

2021